Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
György Németh, I. Laszlovszky, Pál Czobor, et al.
The Lancet (2017) Vol. 389, Iss. 10074, pp. 1103-1113
Closed Access | Times Cited: 306

Showing 1-25 of 306 citing articles:

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>
Christoph U. Correll, Nina R. Schooler
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 519-534
Open Access | Times Cited: 553
Current Concepts and Treatments of Schizophrenia
Piotr Stępnicki, Magda Kondej, Agnieszka A. Kaczor
Molecules (2018) Vol. 23, Iss. 8, pp. 2087-2087
Open Access | Times Cited: 463
Negative symptoms of schizophrenia: new developments and unanswered research questions
Silvana Galderisi, Armida Mucci, Robert W. Buchanan, et al.
The Lancet Psychiatry (2018) Vol. 5, Iss. 8, pp. 664-677
Closed Access | Times Cited: 436
Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes
Stephen M. Stahl
CNS Spectrums (2017) Vol. 22, Iss. 5, pp. 375-384
Open Access | Times Cited: 225
Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
Stephen M. Stahl, Sarah Laredo, Debbi Ann Morrissette
Therapeutic Advances in Psychopharmacology (2020) Vol. 10, pp. 204512532090575-204512532090575
Open Access | Times Cited: 216
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
Marc Krause, Yikang Zhu, Maximilian Huhn, et al.
European Archives of Psychiatry and Clinical Neuroscience (2018) Vol. 268, Iss. 7, pp. 625-639
Open Access | Times Cited: 182
EPA guidance on treatment of negative symptoms in schizophrenia
Silvana Galderisi, Stefan Kaiser, István Bitter, et al.
European Psychiatry (2021) Vol. 64, Iss. 1
Open Access | Times Cited: 133
Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants
Giovanni Ostuzzi, Federico Bertolini, Federico Tedeschi, et al.
World Psychiatry (2022) Vol. 21, Iss. 2, pp. 295-307
Open Access | Times Cited: 76
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
William P. Horan, Steven D. Targum, Amy Claxton, et al.
Schizophrenia Research (2024) Vol. 274, pp. 57-65
Open Access | Times Cited: 17
Anhedonia in depression and schizophrenia: A transdiagnostic challenge
Clare Lambert, Susana Da Silva, Amanda K. Ceniti, et al.
CNS Neuroscience & Therapeutics (2018) Vol. 24, Iss. 7, pp. 615-623
Open Access | Times Cited: 129
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
Filippo Corponi, Chiara Fabbri, István Bitter, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 9, pp. 971-985
Open Access | Times Cited: 122
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO
Ragy R. Girgis, Mark Slifstein, Deepak Cyril D’Souza, et al.
Psychopharmacology (2016) Vol. 233, Iss. 19-20, pp. 3503-3512
Open Access | Times Cited: 116
Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia
Leandro Valiengo, Stephan Goerigk, Pedro Caldana Gordon, et al.
JAMA Psychiatry (2019) Vol. 77, Iss. 2, pp. 121-121
Open Access | Times Cited: 113
Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, et al.
World Psychiatry (2019) Vol. 18, Iss. 2, pp. 208-224
Open Access | Times Cited: 107
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
Wolfgang Fleischhacker, Silvana Galderisi, I. Laszlovszky, et al.
European Psychiatry (2019) Vol. 58, pp. 1-9
Open Access | Times Cited: 103
Primary, Enduring Negative Symptoms: An Update on Research
Brian Kirkpatrick, Armida Mucci, Silvana Galderisi
Schizophrenia Bulletin (2017) Vol. 43, Iss. 4, pp. 730-736
Open Access | Times Cited: 93
Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment
Indrit Bègue, Stefan Kaiser, Matthias Kirschner
Neuroscience & Biobehavioral Reviews (2020) Vol. 116, pp. 74-88
Open Access | Times Cited: 92
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 59
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe
Dragana Bugarski‐Kirola, Celso Arango, Maurizio Fava, et al.
The Lancet Psychiatry (2021) Vol. 9, Iss. 1, pp. 46-58
Closed Access | Times Cited: 58
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends
Michel Sabé, Chaomei Chen, Natacha Perez, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 144, pp. 104979-104979
Open Access | Times Cited: 52
Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
Vanja Mandić-Maravić, Roberto Grujičić, Luka Milutinovic, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 48
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Gilly Wolf, Sandeep Singh, Karin Blakolmer, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 44-58
Closed Access | Times Cited: 38
Psychosis superspectrum II: neurobiology, treatment, and implications
Roman Kotov, William T. Carpenter, David C. Cicero, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 5, pp. 1293-1309
Closed Access | Times Cited: 9
Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia
Jing Huang, AnMei Chen, Hua Jin, et al.
The Journal of Clinical Psychiatry (2025) Vol. 86, Iss. 1
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top